

James W Hodge

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/135132/publications.pdf>

Version: 2024-02-01

138
papers

12,924
citations

23500

58
h-index

27345

106
g-index

163
all docs

163
docs citations

163
times ranked

13034
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. <i>Journal of Experimental Medicine</i> , 2006, 203, 1259-1271.	4.2	1,389
2	Consensus guidelines for the detection of immunogenic cell death. <i>Oncolmunology</i> , 2014, 3, e955691.	2.1	686
3	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610
4	Sublethal Irradiation of Human Tumor Cells Modulates Phenotype Resulting in Enhanced Killing by Cytotoxic T Lymphocytes. <i>Cancer Research</i> , 2004, 64, 7985-7994.	0.4	489
5	Irradiation of Tumor Cells Up-Regulates Fas and Enhances CTL Lytic Activity and CTL Adoptive Immunotherapy. <i>Journal of Immunology</i> , 2003, 170, 6338-6347.	0.4	429
6	External Beam Radiation of Tumors Alters Phenotype of Tumor Cells to Render Them Susceptible to Vaccine-Mediated T-Cell Killing. <i>Cancer Research</i> , 2004, 64, 4328-4337.	0.4	410
7	Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 3353-3362.	3.2	357
8	Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. <i>Oncotarget</i> , 2014, 5, 403-416.	0.8	331
9	Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. <i>Frontiers in Immunology</i> , 2015, 6, 588.	2.2	317
10	Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 516-524.	12.5	288
11	Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 663-674.	2.0	279
12	Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. <i>International Journal of Cancer</i> , 2013, 133, 624-636.	2.3	225
13	Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma. <i>Clinical Cancer Research</i> , 2008, 14, 3060-3069.	3.2	208
14	Combination of Docetaxel and Recombinant Vaccine Enhances T-Cell Responses and Antitumor Activity: Effects of Docetaxel on Immune Enhancement. <i>Clinical Cancer Research</i> , 2008, 14, 3536-3544.	3.2	207
15	Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1001-1011.	1.9	187
16	Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. <i>Vaccine</i> , 1997, 15, 759-768.	1.7	170
17	Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine. <i>Journal of Translational Medicine</i> , 2014, 12, 294.	1.8	144
18	An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele. <i>Oncotarget</i> , 2016, 7, 86359-86373.	0.8	143

#	ARTICLE	IF	CITATIONS
19	IL-15 superagonist/IL-15R α Sushi-Fc fusion complex (IL-15SA/IL-15R α Su-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8 $^{+}$ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas. <i>Oncotarget</i> , 2016, 7, 16130-16145.	0.8	138
20	The Tipping Point for Combination Therapy: Cancer Vaccines With Radiation, Chemotherapy, or Targeted Small Molecule Inhibitors. <i>Seminars in Oncology</i> , 2012, 39, 323-339.	0.8	132
21	Multiple Costimulatory Modalities Enhance CTL Avidity. <i>Journal of Immunology</i> , 2005, 174, 5994-6004.	0.4	128
22	Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study. <i>Clinical Cancer Research</i> , 2020, 26, 4268-4279.	3.2	126
23	Selective Induction of High Avidity CTL by Altering the Balance of Signals from APC. <i>Journal of Immunology</i> , 2003, 170, 2523-2530.	0.4	120
24	Tumor Cells Surviving Exposure to Proton or Photon Radiation Share a Common Immunogenic Modulation Signature, Rendering Them More Sensitive to T Cell-Mediated Killing. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 120-130.	0.4	117
25	Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy. <i>International Journal of Cancer</i> , 2012, 130, 1948-1959.	2.3	115
26	Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer. <i>Cancer Immunology Research</i> , 2014, 2, 133-141.	1.6	115
27	Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer. <i>Oral Oncology</i> , 2019, 95, 127-135.	0.8	103
28	Abscopal Regression of Antigen Disparate Tumors by Antigen Cascade After Systemic Tumor Vaccination in Combination with Local Tumor Radiation. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2012, 27, 12-22.	0.7	101
29	A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): Safety and immunogenicity in a non-human primate. <i>International Journal of Cancer</i> , 1995, 63, 231-237.	2.3	99
30	The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells. <i>Oncotarget</i> , 2016, 7, 37762-37772.	0.8	96
31	Acquisition of CD80 (B7-1) by T Cells. <i>Journal of Immunology</i> , 2001, 166, 2505-2513.	0.4	95
32	PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation. <i>Oncolmmunology</i> , 2018, 7, e1395996.	2.1	90
33	In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer. <i>Frontiers in Oncology</i> , 2012, 2, 104.	1.3	89
34	Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells. <i>Oncotarget</i> , 2016, 7, 7390-7402.	0.8	89
35	Combination Chemotherapy and Radiation of Human Squamous Cell Carcinoma of the Head and Neck Augments CTL-Mediated Lysis. <i>Clinical Cancer Research</i> , 2006, 12, 1897-1905.	3.2	85
36	<i>In Vivo</i> Effects of Lattice Radiation Therapy on Local and Distant Lung Cancer: Potential Role of Immunomodulation. <i>Radiation Research</i> , 2014, 182, 149-162.	0.7	85

#	ARTICLE	IF	CITATIONS
37	Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab. <i>Oncotarget</i> , 2016, 7, 33498-33511.	0.8	85
38	Vaccine therapy of established tumors in the absence of autoimmunity. <i>Clinical Cancer Research</i> , 2003, 9, 1837-49.	3.2	83
39	The Requirement of Multimodal Therapy (Vaccine, Local Tumor Radiation, and Reduction of Suppressor) Tj ETQq1 1,0,784314,rgBT /C	3.2	79
40	Induction of an Antigen Cascade by Diversified Subcutaneous/Intratumoral Vaccination Is Associated with Antitumor Responses. <i>Clinical Cancer Research</i> , 2005, 11, 2416-2426.	3.2	79
41	PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations. , 2020, 8, e000450.		79
42	Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. <i>Cancer Research</i> , 2002, 62, 5770-7.	0.4	79
43	Vaccination with a Recombinant <i>Saccharomyces cerevisiae</i> Expressing a Tumor Antigen Breaks Immune Tolerance and Elicits Therapeutic Antitumor Responses. <i>Clinical Cancer Research</i> , 2008, 14, 4316-4325.	3.2	76
44	Combining radiation, immunotherapy, and antiangiogenesis agents in the management of cancer: the Three Musketeers or just another quixotic combination?. <i>Molecular BioSystems</i> , 2009, 5, 1262.	2.9	75
45	Combination Therapy with a Second-Generation Androgen Receptor Antagonist and a Metastasis Vaccine Improves Survival in a Spontaneous Prostate Cancer Model. <i>Clinical Cancer Research</i> , 2013, 19, 6205-6218.	3.2	75
46	Enhanced Tumor Control with Combination mTOR and PD-L1 Inhibition in Syngeneic Oral Cavity Cancers. <i>Cancer Immunology Research</i> , 2016, 4, 611-620.	1.6	73
47	Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. <i>Oncology</i> , 2008, 22, 1064-70; discussion 1075, 1080-1, 1084.	0.4	72
48	Radiation-Induced Modulation of Costimulatory and Coinhibitory T-Cell Signaling Molecules on Human Prostate Carcinoma Cells Promotes Productive Antitumor Immune Interactions. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2014, 29, 153-161.	0.7	71
49	Vaccines based on whole recombinant <i>Saccharomyces cerevisiae</i> cells. <i>FEMS Yeast Research</i> , 2010, 10, 1060-1069.	1.1	69
50	Therapeutic Cancer Vaccines. <i>Advances in Cancer Research</i> , 2014, 121, 67-124.	1.9	68
51	Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody. <i>Oncotarget</i> , 2017, 8, 8807-8817.	0.8	68
52	Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 1227-1242.	2.0	66
53	Cancer Vaccines: Preclinical Studies and Novel Strategies. <i>Advances in Cancer Research</i> , 2006, 95, 115-145.	1.9	64
54	The Use of Chelated Radionuclide (Samarium-153-Ethylendiaminetetramethylenephosphonate) to Modulate Phenotype of Tumor Cells and Enhance T Cell-Mediated Killing. <i>Clinical Cancer Research</i> , 2008, 14, 4241-4249.	3.2	64

#	ARTICLE	IF	CITATIONS
55	Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway. <i>Oncotarget</i> , 2014, 5, 9335-9348.	0.8	64
56	From Immunogenic Cell Death to Immunogenic Modulation: Select Chemotherapy Regimens Induce a Spectrum of Immune-Enhancing Activities in the Tumor Microenvironment. <i>Frontiers in Oncology</i> , 2021, 11, 728018.	1.3	63
57	Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine. <i>Oncotarget</i> , 2013, 4, 1777-1790.	0.8	63
58	Sublethal exposure to alpha radiation (223Ra dichloride) enhances various carcinomas' sensitivity to lysis by antigen-specific cytotoxic T lymphocytes through calreticulin-mediated immunogenic modulation. <i>Oncotarget</i> , 2016, 7, 86937-86947.	0.8	63
59	Anti-Tumor Immunity Elicited by a Recombinant Vaccinia Virus Expressing CD70 (CD27L). <i>Human Gene Therapy</i> , 1999, 10, 1095-1103.	1.4	62
60	Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines. <i>Cancer Immunology Research</i> , 2014, 2, 1090-1102.	1.6	62
61	Unlocking the Combination: Potentiation of Radiation-Induced Antitumor Responses with Immunotherapy. <i>Radiation Research</i> , 2014, 182, 126-138.	0.7	62
62	Immune Consequences of Tyrosine Kinase Inhibitors that Synergize with Cancer Immunotherapy. <i>Cancer Cell & Microenvironment</i> , 2015, 2, .	0.8	61
63	Recombinant <i>Saccharomyces cerevisiae</i> (yeast-CEA) as a potent activator of murine dendritic cells. <i>Vaccine</i> , 2008, 26, 509-521.	1.7	60
64	Soluble CD27-Pool in Humans May Contribute to T Cell Activation and Tumor Immunity. <i>Journal of Immunology</i> , 2013, 190, 6250-6258.	0.4	59
65	Carcinoembryonic antigen as a target for cancer vaccines. <i>Cancer Immunology, Immunotherapy</i> , 1996, 43, 127-134.	2.0	58
66	Combination Therapy with Local Radiofrequency Ablation and Systemic Vaccine Enhances Antitumor Immunity and Mediates Local and Distal Tumor Regression. <i>PLoS ONE</i> , 2013, 8, e70417.	1.1	57
67	Enhancing immune responses to tumor-associated antigens. <i>Cancer Biology and Therapy</i> , 2009, 8, 1440-1449.	1.5	56
68	Immunotherapy utilizing the combination of natural killer' and antibody dependent cellular cytotoxicity (ADCC)' mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition. , 2018, 6, 133.		56
69	Harnessing the Potential of Radiation-Induced Immune Modulation for Cancer Therapy. <i>Cancer Immunology Research</i> , 2013, 1, 280-284.	1.6	55
70	An IL-15 superagonist/IL-15R' fusion complex protects and rescues NK cell-cytotoxic function from TGF- β 1-mediated immunosuppression. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 675-689.	2.0	55
71	Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses. <i>Cancer Research</i> , 2003, 63, 7942-9.	0.4	55
72	TRICOM Vector Based Cancer Vaccines. <i>Current Pharmaceutical Design</i> , 2006, 12, 351-361.	0.9	53

#	ARTICLE	IF	CITATIONS
73	Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types. <i>Oncolimmunology</i> , 2018, 7, e1466018.	2.1	51
74	Serum Antibodies to Blood Group A Predict Survival on PROSTVAC-VF. <i>Clinical Cancer Research</i> , 2013, 19, 1290-1299.	3.2	50
75	Costimulatory Molecules as Adjuvants for Immunotherapy. <i>Frontiers in Bioscience - Landmark</i> , 2006, 11, 788.	3.0	49
76	Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells. <i>Clinical Cancer Research</i> , 2020, 26, 679-689.	3.2	49
77	PART V. Modulation of Antitumor Vaccine Strategies Preclinical and Clinical Studies of Recombinant Poxvirus Vaccines for Carcinoma Therapy. <i>Critical Reviews in Immunology</i> , 2007, 27, 451-462.	1.0	49
78	Construction and Characterization of a Recombinant Vaccinia Virus Expressing Murine Intercellular Adhesion Molecule-1: Induction and Potentiation of Antitumor Responses. <i>Human Gene Therapy</i> , 1997, 8, 851-860.	1.4	46
79	Rationale for IL-15 superagonists in cancer immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 705-709.	1.4	46
80	Vaccines with Enhanced Costimulation Maintain High Avidity Memory CTL. <i>Journal of Immunology</i> , 2005, 175, 3715-3723.	0.4	45
81	Radiation-induced survival responses promote immunogenic modulation to enhance immunotherapy in combinatorial regimens. <i>Oncolimmunology</i> , 2014, 3, e28643.	2.1	44
82	Natural Born Killers: NK Cells in Cancer Therapy. <i>Cancers</i> , 2020, 12, 2131.	1.7	44
83	Overcoming hypoxia-induced functional suppression of NK cells. , 2020, 8, e000246.		44
84	Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies. , 2018, 6, 59.		43
85	Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 1173-1183.	2.0	41
86	Effect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine. <i>International Journal of Cancer</i> , 2010, 127, 1603-1613.	2.3	41
87	Humoral response to a viral glycan correlates with survival on PROSTVAC-VF. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E1749-58.	3.3	41
88	Combining radiation and immunotherapy for synergistic antitumor therapy. <i>Current Opinion in Molecular Therapeutics</i> , 2009, 11, 37-42.	2.8	41
89	Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK. <i>JCI Insight</i> , 2019, 4, .	2.3	40
90	Intratumoral Vaccination and Diversified Subcutaneous/ Intratumoral Vaccination with Recombinant Poxviruses Encoding a Tumor Antigen and Multiple Costimulatory Molecules. <i>Clinical Cancer Research</i> , 2004, 10, 1090-1099.	3.2	39

#	ARTICLE	IF	CITATIONS
91	Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 397-408.	2.0	39
92	The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy. <i>Molecular Therapy - Oncolytics</i> , 2021, 23, 266-276.	2.0	38
93	ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody. <i>International Journal of Cancer</i> , 2017, 141, 583-593.	2.3	37
94	Defining the Molecular Signature of Chemotherapy-Mediated Lung Tumor Phenotype Modulation and Increased Susceptibility to T-Cell Killing. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2012, 27, 23-35.	0.7	36
95	Amplification of the lytic potential of effector/memory CD8+ cells by vector-based enhancement of ICAM-1 (CD54) in target cells: implications for intratumoral vaccine therapy. <i>Cancer Gene Therapy</i> , 2004, 11, 665-680.	2.2	35
96	Identification of an interferon-gamma-inducible carcinoembryonic antigen (CEA) CD8(+) T-cell epitope, which mediates tumor killing in CEA transgenic mice. <i>Cancer Research</i> , 2002, 62, 5058-64.	0.4	35
97	Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve. , 2021, 9, e001691.		34
98	The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic. <i>Oncotarget</i> , 2015, 6, 31344-31359.	0.8	32
99	Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells. <i>ELife</i> , 2020, 9, .	2.8	32
100	Vaccine-Mediated Immunotherapy Directed against a Transcription Factor Driving the Metastatic Process. <i>Cancer Research</i> , 2014, 74, 1945-1957.	0.4	31
101	Combination Regimens of Radiation Therapy and Therapeutic Cancer Vaccines: Mechanisms and Opportunities. <i>Seminars in Radiation Oncology</i> , 2015, 25, 46-53.	1.0	30
102	Attacking malignant cells that survive therapy. <i>Oncolmmunology</i> , 2013, 2, e26937.	2.1	29
103	Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen. <i>Vaccine</i> , 2009, 27, 4475-4482.	1.7	28
104	A recombinant vector expressing transgenes for four T-cell costimulatory molecules (OX40L, B7-1,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 enhanced cytokine production. <i>Cellular Immunology</i> , 2003, 222, 45-57.	1.4	27
105	Dose-dependent enhancement of T-lymphocyte priming and CTL lysis following ionizing radiation in an engineered model of oral cancer. <i>Oral Oncology</i> , 2017, 71, 87-94.	0.8	26
106	Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy. <i>Clinical Cancer Research</i> , 2020, 26, 704-716.	3.2	26
107	A poxviral-based cancer vaccine targeting the transcription factor twist inhibits primary tumor growth and metastases in a model of metastatic breast cancer and improves survival in a spontaneous prostate cancer model. <i>Oncotarget</i> , 2015, 6, 28194-28210.	0.8	26
108	Androgen deprivation therapy sensitizes triple negative breast cancer cells to immune-mediated lysis through androgen receptor independent modulation of osteoprotegerin. <i>Oncotarget</i> , 2016, 7, 23498-23511.	0.8	25

#	ARTICLE	IF	CITATIONS
109	Combination Therapy of an Orthotopic Renal Cell Carcinoma Model Using Intratumoral Vector-Mediated Costimulation and Systemic Interleukin-2. <i>Clinical Cancer Research</i> , 2007, 13, 1936-1946.	3.2	23
110	Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack. , 2015, 3, 52.		22
111	Vector-based delivery of tumor-associated antigens and T-cell co-stimulatory molecules in the induction of immune responses and anti-tumor immunity. <i>Cancer Detection and Prevention</i> , 2002, 26, 275-291.	2.1	19
112	Hadley J. Sharp, Elizabeth K. Wansley, Charlie T. Garnett, Mala Chakraborty, Kevin Camphausen, Jeffrey Schlom, James W. Hodge. <i>Frontiers in Bioscience - Landmark</i> , 2007, 12, 4900.	3.0	19
113	Cancer vaccines targeting carcinoembryonic antigen: state-of-the-art and future promise. <i>Expert Review of Vaccines</i> , 2013, 12, 617-629.	2.0	18
114	Combination therapy with an OX40L fusion protein and a vaccine targeting the transcription factor twist inhibits metastasis in a murine model of breast cancer. <i>Oncotarget</i> , 2017, 8, 90825-90841.	0.8	18
115	ABO blood type correlates with survival on prostate cancer vaccine therapy. <i>Oncotarget</i> , 2015, 6, 32244-32256.	0.8	18
116	Identification and characterization of enhancer agonist human cytotoxic T-cell epitopes of the human papillomavirus type 16 (HPV16) E6/E7. <i>Vaccine</i> , 2017, 35, 2605-2611.	1.7	17
117	A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab. <i>Journal of Neurosurgery</i> , 2018, 128, 1419-1427.	0.9	17
118	Prostate-specific antigen bounce predicts for a favorable prognosis following brachytherapy: a meta-analysis. <i>Journal of Contemporary Brachytherapy</i> , 2013, 4, 210-214.	0.4	14
119	Stay on Target: Reengaging Cancer Vaccines in Combination Immunotherapy. <i>Vaccines</i> , 2021, 9, 509.	2.1	14
120	A phase II randomized clinical trial of samarium-153 EDTMP (Sm-153) with or without PSA-TRICOM vaccine in metastatic castration-resistant prostate cancer (mCRPC) after docetaxel.. <i>Journal of Clinical Oncology</i> , 2013, 31, 102-102.	0.8	14
121	General Keynote: Vaccine Strategies for the Therapy of Ovarian Cancer. <i>Gynecologic Oncology</i> , 2003, 88, S97-S104.	0.6	13
122	Exploiting off-target effects of estrogen deprivation to sensitize estrogen receptor negative breast cancer to immune killing. , 2021, 9, e002258.		11
123	Therapy of Established Tumors with Rationally Designed Multiple Agents Targeting Diverse Immune-Tumor Interactions: Engage, Expand, Enable. <i>Cancer Immunology Research</i> , 2021, 9, 239-252.	1.6	11
124	Interim analysis of a phase II randomized clinical trial of samrium-153 (Sm-153) with or without PSA-TRICOM vaccine in metastatic castration-resistant prostate cancer after docetaxel.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2526-2526.	0.8	11
125	A pan inhibitor of DASH family enzymes induces immunogenic modulation and sensitizes murine and human carcinoma cells to antigen-specific cytotoxic T lymphocyte killing: implications for combination therapy with cancer vaccines. <i>Vaccine</i> , 2014, 32, 3223-3231.	1.7	10
126	Vaccine Increases the Diversity and Activation of Intratumoral T Cells in the Context of Combination Immunotherapy. <i>Cancers</i> , 2021, 13, 968.	1.7	9

#	ARTICLE	IF	CITATIONS
127	Vaccination with a recombinant vaccinia vaccine containing the B7-1 co-stimulatory molecule causes no significant toxicity and enhances T cell-mediated cytotoxicity. International Journal of Cancer, 2000, 85, 508-517.	2.3	8
128	Combinatorial Natural Killer Cell-based Immunotherapy Approaches Selectively Target Chordoma Cancer Stem Cells. Cancer Research Communications, 2021, 1, 127-139.	0.7	8
129	Next Generation Therapeutic Strategies: Evolving cancer immunotherapy through agents that Engage , Expand and Enable the anti-tumor immune response. Immunomedicine, 2021, 1, e1020.	0.7	6
130	Improving clinical benefit for prostate cancer patients through the combination of androgen deprivation and immunotherapy. Oncoimmunology, 2015, 4, e1009303.	2.1	5
131	A phase I/II study of bintrafusp alfa and NHS-IL12 in combination with docetaxel in adults with metastatic castration sensitive (mCSPC) and castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2021, 39, TPS5096-TPS5096.	0.8	3
132	Cancer vaccine development. Expert Opinion on Investigational Drugs, 1998, 7, 1439-1452.	1.9	2
133	Recombinant TRICOM-based Therapeutic Cancer Vaccines. , 2013, , 309-331.		1
134	Abstract 632: Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. , 2014, , .		1
135	The IDO inhibitor INCB024360 to enhance dendritic cell immunogenicity and anti-tumor immunity in vitro.. Journal of Clinical Oncology, 2015, 33, e14012-e14012.	0.8	1
136	Design, development, and translation of poxvirus-based vaccines for cancer. , 2011, , 56-77.		1
137	Combining radiation and therapeutic cancer vaccines: a synergistic approach. Breast Cancer Management, 2012, 1, 325-335.	0.2	0
138	Immunotherapy utilizing the combined use of NK and ADCC mediating agents with PARP inhibition.. Journal of Clinical Oncology, 2018, 36, 5021-5021.	0.8	0